<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023460</url>
  </required_header>
  <id_info>
    <org_study_id>HortONS</org_study_id>
    <nct_id>NCT05023460</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Cluster Headache With TENS and ONS</brief_title>
  <acronym>HortONS</acronym>
  <official_title>Treatment of Chronic Cluster Headache (Horton's Headache) With Transcutaneous Electrical Nerve Stimulation and Occipital Nerve Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an investigator-initiated, prospective, randomized, placebo-controlled, double&#xD;
      blind clinical trial that aims to investigate the effect of transcutaneous electrical nerve&#xD;
      stimulation (TENS) and occipital nerve stimulation (ONS) on attack frequency and severity in&#xD;
      patients with chronic cluster headache (CH).&#xD;
&#xD;
      Study outline&#xD;
&#xD;
      Month 1: Baseline. Establishment of a baseline profile of the participants CH attacks&#xD;
      (severity, duration, medicine utilization etc), health-related quality of life (QoL) and&#xD;
      symptoms of anxiety and depression. No active treatment. Follow-up visit after 30 days.&#xD;
&#xD;
      Months 2-4: TENS period. All participants will receive TENS-treatment. Clinical follow-up&#xD;
      visit by the end of month four.&#xD;
&#xD;
      Months 5-7: Double-blinded, randomized experimental period. All participants will have an&#xD;
      ONS-system (lead, impulse generator) implanted and will be randomized 1:1 to receive either&#xD;
      1) burst (paresthesia-free) ONS or 2) placebo (deactivated ONS system). Clinical follow-up&#xD;
      visit by the end of month seven.&#xD;
&#xD;
      Months 8-10: Open label period. All participants will receive tonic (conventional,&#xD;
      paresthesia-inducing) ONS.&#xD;
&#xD;
      Clinical follow-up visit by the end of month ten.&#xD;
&#xD;
      During every study phase each participant will fill out a weekly electronic headache&#xD;
      registration as well as answering questionnaires regarding health-related quality of life and&#xD;
      symptoms of anxiety and depression before every follow-up visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30% reduction in CH attack frequency with TENS- and ONS-treatment</measure>
    <time_frame>Primary evaluation through month 4 (TENS) and 7 (ONS, blinded)</time_frame>
    <description>Proportion of participants with a positive treatment outcome of a 30% reduction in CH attack frequency compared to baseline.&#xD;
A CH attack is here defined as any attack recognised by the patient as a CH attack.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emerged adverse events [safety] in TENS treatment</measure>
    <time_frame>Evaluation at month 4</time_frame>
    <description>Treatment related adverse events and adverse device effects will be registered on an ongoing basis. Serious events will be handled immediately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emerged adverse events [safety] in ONS treatment</measure>
    <time_frame>Evaluation at month 7 (burst ONS) and 10 (tonic ONS)</time_frame>
    <description>Treatment related adverse events and adverse device effects will be registered on an ongoing basis. Serious events will be handled immediately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30% reduction of pain intensity in CH attacks</measure>
    <time_frame>Through month 4, 7 and 10</time_frame>
    <description>Weekly self reported pain intensity on a numeric rating scale from 0-10 with 0 being &quot;no pain&quot; and 10 &quot;the worst possible pain&quot;.&#xD;
Proportion of participants with a positive treatment outcome of a 30% reduction in pain intensity during CH attacks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of TENS as a predictor for the efficacy of ONS treatment</measure>
    <time_frame>Through month 4 and 10</time_frame>
    <description>Comparison will be made of headache data from the last month of treatment with TENS and tonic ONS, respectively, to evaluate whether a 30% reduction in CH attack duration with TENS-treatment correlates to a 30% reduction in CH attack duration with ONS-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inferiority study: Burst ONS versus tonic ONS</measure>
    <time_frame>Through month 7 and 10</time_frame>
    <description>Comparing treatment outcome of burst ONS and tonic ONS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-perceived Global Impression of Change (PGIC)</measure>
    <time_frame>At month 4, 7 and 10</time_frame>
    <description>The number of participants who rates their condition 'much improved' or 'very much improved' as assessed by PGIC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in background headache</measure>
    <time_frame>At month 4, 7 and 10</time_frame>
    <description>Proportion of participants reporting a reduction in background headache. A positive treatment outcome will be defined as a two-point improvement on a four-point scale compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital anxiety and depression scale (HADS)</measure>
    <time_frame>At month 4, 7 and 10</time_frame>
    <description>HADS is a self-assessment questionnaire consisting of seven items each for depression and anxiety sub-scales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level.&#xD;
HADS score will be evaluated at every follow up and compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (EuroQoL 5D-5L)</measure>
    <time_frame>At month 4, 7 and 10</time_frame>
    <description>The EQ 5D-5L is a well-established measure of health-related quality of life that is quantified as a utility (a measure of quality of life between 0 and 1) based on a danish value set. Furthermore a total score that ranges from 0-100 (visual analog scale), a higher score indicates better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported sleep quality</measure>
    <time_frame>At month 4, 7 and 10</time_frame>
    <description>Proportion af participants reporting a positive treatment outcome defined as a two-point improvement on a four-point scale compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Cluster Headache</condition>
  <condition>Primary Headache Disorder</condition>
  <condition>Headache</condition>
  <condition>Cluster Headache</condition>
  <condition>Pain</condition>
  <condition>Cephalgia</condition>
  <condition>Trigeminal Autonomic Cephalgia</condition>
  <arm_group>
    <arm_group_label>Paresthesia-free (burst) ONS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implanted lead and impulse generator (IPG), paresthesia-free (burst) active stimulation.&#xD;
Lead implanted subcutaneously over greater occipital nerves. Implanted IPG capable of providing paresthesia-free stimulation continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Implanted lead and IPG, deactivated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paresthesia-free (burst) ONS</intervention_name>
    <description>Stimulation intensity target of 60% of paresthesia threshold.</description>
    <arm_group_label>Paresthesia-free (burst) ONS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ONS system deactivated</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years and above&#xD;
&#xD;
          2. Signed informed written consent&#xD;
&#xD;
          3. Diagnosed with chronic CH according to the ICHD-3 criteria&#xD;
&#xD;
          4. 15 or more CH attacks per month&#xD;
&#xD;
          5. Stable use of preventive headache medication one month prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other ongoing neuromodulation therapy&#xD;
&#xD;
          2. Current alcohol and/or drug abuse&#xD;
&#xD;
          3. Severe psychiatric disorder&#xD;
&#xD;
          4. Other chronic primary or chronic secondary headache disorder (e.g. chronic migraine)&#xD;
&#xD;
          5. Major posterior neck surgery in C2-C3 level and above&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Treatment with oral steroids or GON injection within one month of study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ida S Fogh-Andersen, MD PhD fellow</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaare Meier, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Christian H Sørensen, MD PhD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rigmor H Jensen, MD PhD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Danish Headache Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaare S Meier, MD PhD</last_name>
    <phone>+4523882214</phone>
    <email>kaamei@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ida S Fogh-Andersen, MD PhD fellow</last_name>
    <phone>+4529414695</phone>
    <email>isfa@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida S Fogh-Andersen, PhD-fellow</last_name>
      <phone>+4529414695</phone>
      <email>isfa@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kaare Meier, PhD</last_name>
      <email>kaamei@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Jens Christian H Sørensen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Ida Stisen Fogh-Andersen</investigator_full_name>
    <investigator_title>PhD fellow</investigator_title>
  </responsible_party>
  <keyword>Occipital nerve stimulation</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Transcutaneous electrical nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache Disorders</mesh_term>
    <mesh_term>Headache Disorders, Primary</mesh_term>
    <mesh_term>Trigeminal Autonomic Cephalalgias</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

